dr. ayman al sibaie

35
Endovascular Management of Thoracic Aortic injury Dr. Ayman Al-Sibaie Consultant of Interventional Radiology Rashid Hospital Dubai

Upload: pairs-pan-arab-interventional-radiology-societ

Post on 10-Jan-2017

200 views

Category:

Health & Medicine


0 download

TRANSCRIPT

Page 1: DR. AYMAN AL SIBAIE

Endovascular Management of Thoracic Aortic injury

Dr. Ayman Al-SibaieConsultant of Interventional Radiology

Rashid Hospital Dubai

Page 2: DR. AYMAN AL SIBAIE

Thoracic Aortic Pathology• Aortic Aneurysms• Thoracic Aortic Dissection• Aortic Ulcers and IM Hematomas• Traumatic Transection• Other Aortic Pathology

Page 3: DR. AYMAN AL SIBAIE

Blunt Thoracic Aortic Injury

Described by Vesalius, 1557 – Fall from horse – Most common distal to L SCA• Motor vehicles involved 92% • Falls, crush injury • Immediate death 60% - 80%

Arthurs et al. JVS. 2009;49:988-94. Demetriades. JACS. 2011;214:247-59.JACS.

Page 4: DR. AYMAN AL SIBAIE
Page 5: DR. AYMAN AL SIBAIE

Grading Aortic Injury

Azizzadeh, et al. JVS. 2009;49:1403-8.

Page 6: DR. AYMAN AL SIBAIE
Page 7: DR. AYMAN AL SIBAIE
Page 8: DR. AYMAN AL SIBAIE
Page 9: DR. AYMAN AL SIBAIE
Page 10: DR. AYMAN AL SIBAIE

Patient characteristic

• Young • Healthy • Compliance• Follow-up

Page 11: DR. AYMAN AL SIBAIE

Evolution of Management• 1997 – Angio or CTA– Immediate repair – Open surgery• 2013 – CTA– Delayed repair in stable patients – Endovascular when feasible (78%)

Mestral, et al. JACS. 2013;216:1110-1115.

Page 12: DR. AYMAN AL SIBAIE

Long-Term Outcomes• 27 patients from 2001-2011 – 4 Zenith TX1/2– 5 Gore TAG/CTAG – 18 Medtronic Valiant/Valiant-Captiva/Talent• LSAcovered15% • 4% endoleak (Type 1) • 7.4% early mortality • 0% paraplegia, stroke, arm ischemia

Martinelli, et al. JVS. 2013;58(3):832-5

Page 13: DR. AYMAN AL SIBAIE

Long-Term Outcomes

• Median follow-up 60 months – 22 patients – CTA• Graft infolding: 2 patients – Asymptomatic – Captiva 0.5 yr, Gore TAG 5 yr• Migration 2 patients – Asymptomatic – Zenith, 18 and 24 months

Martinelli, et al. JVS. 2013;58(3):832-5

Page 14: DR. AYMAN AL SIBAIE

SVS Clinical Practice Guidelines• Systematic review – 7768 patients

Lee, at al. JVS. 2011;53:187-92.

Page 15: DR. AYMAN AL SIBAIE

SVS Guidelines• TEVAR within 24 hours in stable patient – Barring other serious injuries• Expectant management Grade 1 injury – Repair all others• TEVAR in all age groups • Utilize next-generation devices• Selective revascularization LSA

Lee, at al. JVS. 2011;53:187-92.

Page 16: DR. AYMAN AL SIBAIE

SVS Guidelines• Systemic heparinization with low dose – Individualized to patient• Spinal drainage not routinely indicated• General anesthesia• Open femoral artery access• Follow-up necessary but not standardized – CTA vs MRA, frequency

Lee, at al. JVS. 2011;53:187-92.

Page 17: DR. AYMAN AL SIBAIE

RESCUE Trial• Medtronic Valiant Captiva• Prospective, 20 sites, 50 patients• Blunt thoracic aortic injury• 30-day all-cause mortality• Follow-up 1, 6, 12 months and yearly for 5 years with CTA or MRA

Khoynezhad A, et al. JVS. 2013;57:899-905.

Page 18: DR. AYMAN AL SIBAIE

RESCUE Trial• 68% Grade 3 injury, 18% Grade 1• Proximal aortic diameters 18 mm – 34 mm• Distal aortic diameters 18 mm - 42 mm• Partial or complete coverage LSA 58%• 8% early deaths, 1 possible related to device• No endoleaks

Khoynezhad A, et al. JVS. 2013;57:899-905.

Page 19: DR. AYMAN AL SIBAIE

TAG 08-02 Study

• Gore Conformable TAG (CTAG)• Prospective, 21 sites, 51 patients• Blunt thoracic aortic injury• 30-day all cause mortality• 30-day freedom from major device events• Follow-up 1 and 6 months, annually for 5 years

Farber M, et al. JVS. 2013;53:187-92..

Page 20: DR. AYMAN AL SIBAIE

TAG 08-02 Study• 98% tear >1 cm or more severe• Proximal aortic diameters 17 mm - 33 mm • Distal aortic diameters 16 mm - 34 mm • Partial or complete coverage LSA 63% • 7.8% early deaths, none device related • No MDEs • 2 endoleaks (Type II and unknown)

Farber M, et al. JVS. 2013;53:187-92..

Page 21: DR. AYMAN AL SIBAIE

Impact of New Devices• Smaller diameters – 16-mm diameter aorta• Tighter arches• Increased resistance to infolding – 0.4% with Gore TAG, 0% with Gore CTAG• Increased deployment accuracy

Kasirajan, et al. JVS. 2012;55:652-8.

Page 22: DR. AYMAN AL SIBAIE

Coverage LSA• 20-mm proximal landing zone (IFU)• Median distance LSA to tear: 13.5 (0-36) mm*• 1/3 patients will get arm claudication – Left vertebral artery <3mm (p<.0001)**• Rarely necessary with current devices – 5-mm landing zone adequate

*Khoynezhad, et al. JVS. 2013;57:899-905.**Antonello M, et al. JVS. 2013;57:684-90.

Page 23: DR. AYMAN AL SIBAIE

Follow-Up

• Greatest challenge of TEVAR for trauma• Longest life expectancy • Highly variable patient compliance • Difficult anatomy to image• Structural and physiologic consequences

Page 24: DR. AYMAN AL SIBAIE

Imaging Follow-up• CTA at discharge, 3 - 6 months, 1 year – Consider 2 - 5 year intervals – US and European guidelines• What we do (based on Gestalt) – CTA at discharge, 6 months, 1 year – CTA or MRA + CXR every 2 years – After 10 years, consider 5 year intervals

Lee, et al. JVS. 2011;53:187-92. Grabenwoger, et al. Eur Heart J. 2012;33:1558-63.

Page 25: DR. AYMAN AL SIBAIE

Physiologic Consequences• Post-endograft HPTN reported 2005 – 80% patients <35 with early HPTN – 36% HPTN at ≥13 months, 18% on Rx• Noncompliant endograft • Increased aortic pulse wave velocity • Increased pulse pressure

Tzilalis, et al. J Endovasc Ther. 2005;12:142-3. Tzilalis, et al. Ann Vasc Surg. 2012;26:462-7.

Page 26: DR. AYMAN AL SIBAIE

Aortic Pulse Wave Velocity

Tzilalis, et al. Ann Vasc Surg. 2012;26:462-7.

Page 27: DR. AYMAN AL SIBAIE

Case I

Page 28: DR. AYMAN AL SIBAIE

Case I

Page 29: DR. AYMAN AL SIBAIE

Case II

Page 30: DR. AYMAN AL SIBAIE

Case Report II

Page 31: DR. AYMAN AL SIBAIE

Case Report II

Page 32: DR. AYMAN AL SIBAIE

Case III

Page 33: DR. AYMAN AL SIBAIE

Case III

Page 34: DR. AYMAN AL SIBAIE

Case III

Page 35: DR. AYMAN AL SIBAIE

Summary• TEVAR for ≥Grade 2 injury – Observation Grade 1 injury• Delayed repair in stable patients• New devices resolve structural issues • Follow-up recommendations vague • Long-term outcomes remain unknown